Market capitalization | $639.91m |
Enterprise Value | $522.70m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.73 |
P/S ratio (TTM) P/S ratio | 5.79 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 202.25% |
Revenue (TTM) Revenue | $110.50m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
8 Analysts have issued a Wave Life Sciences Ltd. forecast:
8 Analysts have issued a Wave Life Sciences Ltd. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 111 111 |
202%
202%
|
|
Gross Profit | 102 102 |
281%
281%
|
|
EBITDA | -75 -75 |
41%
41%
|
EBIT (Operating Income) EBIT | -84 -84 |
39%
39%
|
Net Profit | -74 -74 |
44%
44%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
Head office | Singapore |
CEO | Paul Bolno |
Employees | 268 |
Founded | 2012 |
Website | www.wavelifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.